Clinical Trial Update: Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study) [Phase 2]

View source ↗

Summary

A Phase IIa clinical trial is investigating a selective glucocorticoid receptor antagonist for treating PTSD in veterans; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Snippet

Sponsor: VA Office of Research and Development | Conditions: PTSD | Phase 2 | Status: RECRUITING